PLX — Protalix Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- $118.61m
- $99.16m
- $53.40m
- 39
- 46
- 60
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 4.12 | ||
| PEG Ratio (f) | 0.05 | ||
| EPS Growth (f) | 307.69% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.94 | ||
| Price to Tang. Book | 2.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.22 | ||
| EV to EBITDA | 19.05 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.34% | ||
| Return on Equity | 10.42% | ||
| Operating Margin | 7.74% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 62.9 | 38.35 | 47.64 | 65.49 | 53.4 | 74.55 | 119.46 | -0.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -64.13 | +466.77 | +260.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Directors
- Zeev Bronfeld NEC (70)
- Dror Bashan PRE (54)
- Eyal Rubin CFO (45)
- Einat Almon SVP (62)
- Yael Hayon VRD (38)
- Amos Bar-Shalev IND (69)
- Pol Boudes IND (64)
- David Granot IND (74)
- Gwen Melincoff IND (69)
- Aharon Schwartz IND (79)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 30th, 2016
- Public Since
- September 6th, 2010
- No. of Shareholders
- 60
- No. of Employees
- 207
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 79,607,115
- Address
- 2 University Plaza, Suite 100, HACKENSACK, 07601
- Web
- https://protalix.com/
- Phone
- +1 2016969345
- Contact
- Mike Moyer
- Auditors
- Kesselman & Kesselman
Upcoming Events for PLX
Protalix Biotherapeutics Inc Annual Shareholders Meeting
Protalix Biotherapeutics Inc Annual Shareholders Meeting
Q2 2025 Protalix Biotherapeutics Inc Earnings Release
Q3 2025 Protalix Biotherapeutics Inc Earnings Release
Similar to PLX
FAQ
What is the Protalix Biotherapeutics share price?
As of Today at 22:44 UTC, shares in Protalix Biotherapeutics are trading at $1.67. This share price information is delayed by 15 minutes.
How has the Protalix Biotherapeutics share price performed this year?
Shares in Protalix Biotherapeutics last closed at $1.67 and the price had moved by +42.74% over the past 365 days. In terms of relative price strength the Protalix Biotherapeutics share price has outperformed the S&P500 Index by +27.04% over the past year.
What are the analyst and broker recommendations for Protalix Biotherapeutics?
The overall consensus recommendation for Protalix Biotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Protalix Biotherapeutics dividend yield?
Protalix Biotherapeutics does not currently pay a dividend.
Does Protalix Biotherapeutics pay a dividend?
Protalix Biotherapeutics does not currently pay a dividend.
When does Protalix Biotherapeutics next pay dividends?
Protalix Biotherapeutics does not currently pay a dividend.
How do I buy Protalix Biotherapeutics shares?
To buy shares in Protalix Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Protalix Biotherapeutics?
As of the previous close price of $1.67, shares in Protalix Biotherapeutics had a market capitalisation of $132.94m.
Where are Protalix Biotherapeutics shares listed?
Here are the trading details for Protalix Biotherapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: PLX
What kind of share is Protalix Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Protalix Biotherapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Protalix Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in Protalix Biotherapeutics is $14.00. That is 738.32% above the last closing price of $1.67.
Analysts covering Protalix Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of $0.21 for the next financial year.
Find out moreWhat is the trend in the Protalix Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Protalix Biotherapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +17.99%.
As of the last closing price of $1.67, shares in Protalix Biotherapeutics were trading -7.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Protalix Biotherapeutics PE Ratio?
The Protalix Biotherapeutics PE ratio based on its reported earnings over the past 12 months is 4.12. The shares last closed at $1.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Protalix Biotherapeutics?
Protalix Biotherapeutics' management team is headed by:
- Zeev Bronfeld - NEC
- Dror Bashan - PRE
- Eyal Rubin - CFO
- Einat Almon - SVP
- Yael Hayon - VRD
- Amos Bar-Shalev - IND
- Pol Boudes - IND
- David Granot - IND
- Gwen Melincoff - IND
- Aharon Schwartz - IND